Kamada (KMDA) Interest & Investment Income (2012 - 2026)
Kamada's (KMDA) quarterly Interest & Investment Income came in at $434000.0 in Q2 2026, down 4.19% on a YoY basis from $453000.0 in Q2 2025, and up 2.12% quarter-over-quarter from $425000.0 in Q1 2026.
Powered by 
Analysis
Kamada (KMDA) Interest & Investment Income (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Interest & Investment Income for 15 consecutive years, with $434000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income fell 4.19% year-over-year to $434000.0; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (down 22.62% YoY), and the FY2025 full-year result was $1.9 million, down 9.3% from the prior year.
- Interest & Investment Income advanced to $434000.0 in Q2 2026 per KMDA's latest filing, from $425000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $684000.0 in Q4 2024 and bottomed at $1000.0 in Q2 2022.
- Historically, Interest & Investment Income has averaged $328058.8 across 5 years, with a median of $434000.0 in 2026.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income sank 98.99% in 2022, then jumped 1150.0% in 2023.
- Over 5 years, Interest & Investment Income stood at $59000.0 in 2022, then jumped by 740.68% to $496000.0 in 2023, then jumped by 37.9% to $684000.0 in 2024, then plunged by 35.38% to $442000.0 in 2025, then declined by 1.81% to $434000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $434000.0, $425000.0, and $442000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | 434,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 434,000.00 |
| Mar 31, 2026 | 425,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Sep 30, 2025 | 492,000.00 |
| Jun 30, 2025 | 453,000.00 |
| Mar 31, 2025 | 534,000.00 |
| Dec 31, 2024 | 684,000.00 |
| Sep 30, 2024 | 646,000.00 |
| Jun 30, 2024 | 508,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 496,000.00 |
| Sep 30, 2023 | 67,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 18,000.00 |
| Sep 30, 2021 | 68,000.00 |
| Jun 30, 2021 | 99,000.00 |